Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, announces the successful closing of its previously announced acquisition of Nektar Therapeutics’ PEGylation reagent manufacturing business. The new Ampersand portfolio company will be branded Gannet BioChem and will continue to operate out of its state-of-the-art facility in Huntsville, Alabama. With over 30 years of expertise, Gannet BioChem is a proven specialty CDMO leader in developing, scaling, and manufacturing polyethylene glycol (PEG) reagents – critical components in advanced biopharmaceutical and therapeutic products.
Read the full article: Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics’ PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem //
Source: https://www.prnewswire.com/news-releases/ampersand-capital-partners-completes-acquisition-of-nektar-therapeutics-peg-reagent-manufacturing-business-launching-newly-branded-gannet-biochem-302319679.html